RxDoctor Payments Data

Aubrey Wilson, PA

Medical · Chapel Hill, NCNPI 1629348214

Payments from drug & device makers

$2,421in general payments, 2019–2025

Across 27 payments — averaging $89.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$848
  • Sanofi$666
  • GSK$325
  • Pfizer$202
  • Lilly USA, LLC$124
  • Amgen$122
  • plus $134 from 2 others

What the payments were for

  • Food & beverage$2,421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie11$848
Sanofi7$666
GSK3$325
Pfizer2$202
Lilly USA, LLC1$124
Amgen1$122
UCB, Inc.1$121
Johnson & Johnson1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,421 in reported general payments places this provider in the 75th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$14,690
Medicare patients
121
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab46$453,735
Enbrel SureclickEtanercept43$311,891
Taltz AutoinjectorIxekizumab14$131,211
RinvoqUpadacitinib19$122,510
Cosentyx Sensoready (2 Pens)Secukinumab11$79,528
BenlystaBelimumab12$57,177
RasuvoMethotrexate/Pf16$13,807
MethotrexateMethotrexate Sodium189$6,440
Hydroxychloroquine Sulfate129$4,426
Diclofenac Sodium39$1,854
Leucovorin Calcium27$1,648
Colchicine29$1,624
Leflunomide47$1,384
Prednisone87$810
Duloxetine Hcl21$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$848$122,51019 claims
GSKBenlysta$325$57,17712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 878 medical providers in North Carolina.

Other medical in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →